APT MotoVox Group Inc. (MTVX)

[HEMIsphere05]

News

Frozen Food Gift Group Becomes APT Group Inc.

Apr 17, 2014 (ACCESSWIRE via COMTEX) -- On Apr. 16, APT Group Inc. (OTCQB: FROZ) stock volume soared, with 92,118,453 shares changing hands, nearly twice its three-month average volume of 57,140,919 shares.
The surge in stock volume is being fueled in part by the company's Apr. 10 announcement that it has taken the major step to becoming a public company, traded on the stock markets, by completing a Share Exchange Agreement with Frozen Food Gift Group Inc.

APT Group, Inc. comprised of American Performance Technologies, LLC, APT Powersport & Utility Products, LLC, APT IP Holdings, LLC and APT Real Estate, LLC, will be the only entities that remain a part of FROZ.

"APT is poised for rapid growth through our new public company," said Wayne Patterson, CEO. "The combination of our three divisions with focus on emissions testing, disruptive fuel systems and propulsion technologies, and advanced powersport and utility products places us in a globally unique position only held by a few of the very largest companies. We look forward to an exciting 2014 and an even better 2015 and beyond," he added.

Certain outstanding items, such as changes to the public company name and the application for a new ticker symbol have been initiated. These changes will be announced once they are approved by authorities.

On Apr. 16, FROZ's share price closed at 2 cents, unchanged from the share price of the previous day.

Sign up today for timely and hot stock alerts here, or by cutting and pasting the following link in your Web browser:

http://www.pennypickalerts.com

Globalstar Reports Quarterly Revenue Up 10%

In another sector, Mobile satellite service provider Globalstar Inc. (OTCQB: GSAT) stock volume soared Apr. 2, with 1,532,223 shares changing hands

The heavy volume is being fueled in part by Covington, La.-based company's recent release of its 2013 4Q results.

Here are the highlights:

Revenue was $21.0 million for the fourth quarter of 2013 compared to $19.1 million for the fourth quarter of 2012, an increase of 10%, which was due to increases in both service revenue and subscriber equipment revenue.

Net Loss

However Globalstar's net loss increased during the fourth quarter of 2013 reflecting the impact of substantial non-cash charges resulting from an increase in the value of the Company's derivative instruments, which was driven primarily from a 61% increase in the Company's stock price during the fourth quarter of 2013. The company reported a net loss of $234.8 million for the fourth quarter of 2013 compared to $19.0 million for the fourth quarter of 2012.

The increased net loss was due also to several other non-cash items, such as higher interest expense driven by decreases in the amount of interest being capitalized and note conversion activity, as well as higher depreciation expense as the Company placed additional satellites into service during 2013.

Shares of GSAT closed at $2.54 on Apr. 16 up 11 cents from $2.43, the previous day's close.

Sign up today for timely and hot stock alerts here, or by cutting and pasting the following link in your Web browser:

http://www.pennypickalerts.com

Nuvilex Inc. Contracts Clinical Network Service for Late-Phase Clinical Trials

In the biotech sector, Nuvilex, Inc. (OTCQB: NVLX) announced Apr. 15 that it has contracted Clinical Network Services Pty Ltd (CNS), a fully integrated drug development company based in Australia, New Zealand and the United Kingdom, to handle every aspect of Nuvilex's late-phase clinical trials in pancreatic cancer as Nuvilex's Contract Research Organization (CRO).

The trials, which will focus on treatment for advanced stage pancreatic cancer, will involve Nuvilex's pancreatic cancer treatment (a combination of the proprietary "Cell in-a-Box" live-cell encapsulation technology and the cancer drug ifosfamide) which has already proved effective in early stage trials.

"The work we are embarking upon with CNS is an important milestone for Nuvilex, as it represents the next step in proving the value of our Cell-in-the-Box technology and the potential of a better treatment for pancreatic cancer," said Kenneth L. Waggoner, CEO and President of Nuvilex.

To Work With Dr. Daniel Von Hoff

In addition, the Silver-Spring, Md.-based biotech company announced that would be working with Dr. Daniel Von Hoff, a leading figure in pancreatic cancer, to develop its pancreatic cancer and other treatments utilizing its Cell-in-a-Box(R) technology. These are just the latest of several upbeat press releases from the company that is working on optimizing the anticancer effectiveness of cannabinoids.

Gets $2 Million in Initial Funding

On Feb. 24, the company announced that Lincoln Park Capital purchased 8 million in restricted shares of Nuvilex in exchange for an initial $2 million out of $27 million set aside to advance the company's late-phase pancreatic cancer clinical trials.

Over the last year Nuvilex has issued a bevy of positive press releases about how it is positioning itself and recruiting and hiring the top researchers in the medical-marijuana field. But so far, the company has not produced any concrete products or services for the industry. Neville's cannabis business appears to still be in the developmental stage. Still, it has hired the brain power that eventually could make it a real player.

On Apr. 16, NVLX's share price closed at 28 cents, down 4 cents from its closing price of 32 cents the previous day, on volume of 8,279,771 shares.

Sign up today for timely and hot stock alerts here, or by cutting and pasting the following link in your Web browser:

http://www.pennypickalerts.com

Liquidmetal Technologies Inc. Loses $14 Million for Year Ending 2013

Finally, California-based alloy maker Liquidmetal Technologies Inc.'s (OTCQB: LQMT) reported its financial results for the fiscal year ended Dec. 31, 2013.

The company lost about $14 million on revenue of 1 million compared with a loss of $14 million on revenue of $650,000 for the same time period a year before.

Year's Highlights

Liquidmetal spun the financial results as being positive and failed to mention its overall loss in its press release.

Here are the positive highlights as viewed by the company:

- In 2013, 18 prototype shipments were delivered to customers in the aerospace/defense, medical and other industries, which was up 80% from 2012.

- During Q4, the Company increased the authorization for available shares from 500M to 700M and secured a $20 million equity line of credit under a common stock purchase agreement. Utilizing this equity line facility, the Company has raised $3M during Q1 2014.

- During Q4, the company announced the commercial availability of our first non-beryllium based alloy, LM 105. This offers, for the first time, customers and licensees access to the same great material qualities of earlier alloys, without the special handling precautions necessary for beryllium containing materials.

- At year end, the company's IP portfolio included 53 owned or licensed U.S. patents, with an additional 54 patent applications pending. Its patent applications relate to the composition, processing, and application of Liquidmetal alloys.

- We have appointed Paul Hauck as VP of World-Wide Sales and Support effective March 3, 2014. Paul comes to Liquidmetal with a 30-year background in the field of powder metallurgy, including 27 years in Metal Injection Molding (MIM). Paul has been behind the development and growth of MIM start-ups and was a 2013 Distinguished Service to Powder Metallurgy award recipient. He also served 3 terms as the Metal Injection Molding Association President and served 3 terms on the Metal Powder Industries Fed

On Apr. 16, LQMT's share price closed at 18 cents, down 1 cent from its closing price of 19 cents the previous day.

Sign up today for timely and hot stock alerts here, or by cutting and pasting the following link in your Web browser:

http://www.pennypickalerts.com

ABOUT US:

Pennypickalerts.com issues momentum alerts on stocks that can provide gains to day traders.

Pennypickalerts.com provides members with timely information and exclusive alerts on cheap and under-valued stocks in the United States with the potential to deliver gains of 100% - 200% or more.

Pennypickalerts.com monitors and scans the markets for stock related signals as well as any external factors that might bring trading opportunities. Through a vast network of IR professionals Pennypickalerts.com is often in the know of several large investor awareness campaigns being deployed.

Timing is everything when trading Penny Stocks. Gain an Edge by joining the Pennypickalerts.com newsletter and receiving alerts from a Pro-Active team of researchers. Pennypickalerts.com believes traders should have a chance at successfully trading penny stocks and invites traders and investors to be part of the Free VIP membership.

Simply sign up for free and start receiving exclusive alerts.

Subscribe Here: http://www.pennypickalerts.com

Disclosure

Pennypickalerts.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always own due diligence with any potential investment.

http://www.accesswire.com/img.ashx?id=414523

Copyright 2014 ACCESSWIRE
-0-